Clinical trial
A Multicenter, Open-Label, Dose-Finding, Phase 2 Study Evaluating THIO Sequenced With Cemiplimab (LIBTAYO®) in Subjects With Advanced Non-Small Cell Lung Cancer (NSCLC)
NCT05208944 is registered in ClinicalTrials.gov with Maia Biotechnology as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multicenter, Open-Label, Dose-Finding, Phase 2 Study Evaluating THIO Sequenced With Cemiplimab (LIBTAYO®) in Subjects With Advanced Non-Small Cell Lung Cancer (NSCLC)
- Lead sponsor
- Maia Biotechnology
- Phase
- Phase 2
- Overall status
- Active, not recruiting
- Start date
- June 8, 2022
- Completion date
- December 31, 2027
- Enrollment
- 227 (estimated)
- Sites
- 40
Conditions
As the registry lists them; a condition with its own page is linked.